Accordingly, PDE5 inhibitors have been tested for the prevention/treatment of various vascular disorders, including diabetic vasculopathy [6], retinal ischemia/reperfusion injury [7], diabetic nephropathy [8] and Alzheimer’s disease [9]. This evidence concerns the gene PDE5A and retinal ischemia.